Guideline Summary NGC-10815

Guideline Title
EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.

Bibliographic Source(s)

Guideline Status
This is the current release of the guideline.
This guideline meets NGC’s (2013) revised inclusion criteria.

Scope

Disease/Condition(s)
Moderate to severe Alzheimer's disease (AD)

Guideline Category
Management
Treatment

Clinical Specialty
Family Practice
Geriatrics
Neurology

Intended Users
Physician Assistants
Physicians

Guideline Objective(s)
To develop guidelines on the question of whether combined cholinesterase inhibitors (ChEI)/memantine treatment rather than ChEI alone should be used in patients with moderate to severe Alzheimer's disease (AD) to improve global clinical impression (GCI), cognition, behaviour and activities of daily living (ADL)

Target Population
Alzheimer's disease (AD) patients in the moderate to severe disease stage

Interventions and Practices Considered
1. Combined cholinesterase inhibitors (ChEI) and memantine treatment
2. ChEI alone (not recommended)

Major Outcomes Considered
- Global clinical impression (GCI)
- Cognitive functioning
- Behaviour
- Activities of daily living (ADL)
- Adverse events

Methodology

Methods Used to Collect/Select the Evidence
Searches of Electronic Databases

Description of Methods Used to Collect/Select the Evidence
Search Strategy
The time period covered by the literature research was from 01/2004 to 01/2013.
Trials were identified from a search of ALOIS, the specialized register of the Cochrane Dementia and Cognitive Improvement Group, using the search terms "Alzheimer's disease", "donepezil", "E2020", "Aricept", "galantamin", "galantamine", "reminyl", "rivastigmine", "eldeco", "ENA 713" and "ENA-713", "memantine", "combination therapy" and "dual therapy". This register consists of records from major healthcare databases including MEDLINE (Ovid SP), EMBASE (Ovid SP), PsychnFO (Ovid SP), CINAHL (EBSCOhost) and Lilacs (Bireme). It also searches major trial and pharmaceutical industry trials registers. ALOIS covers all randomized controlled trials of interventions for people with dementia, for people with cognitive impairment and for the improvement of, or prevention of decline in, cognitive function in healthy people. It was created in 2008 and represents a free open-access resource. The panellists found 11 publications related to the patients, intervention, comparison, and outcome (PICO) question.

Trial Inclusion

Other than in the study by Schneider et al. which included patients with mild cognitive impairment and mild Alzheimer's disease (AD), the panellists considered only trials if they included moderate to severe AD patients, assessed at least one of the outcomes defined in the PICO question and followed a randomized double-blind, parallel group design. Seven studies fulfilled these criteria. To avoid duplications they excluded those studies which represented post hoc analysis of the original MEM-MD-02 trial, leaving four trials to be included in the analysis.

Number of Source Documents

Four trials were included in the analysis.

Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence

Guideline development followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. The GRADE approach is based on a sequential assessment of the quality of evidence. Figure 6 in the original guideline document provides the GRADE evidence profile. Based on the study design and the results of the meta-analysis this evidence profile classifies the quality of evidence in one of four levels ranging from very low to high for the overall underlying literature for each important outcome.

Methods Used to Analyze the Evidence

Meta-Analysis

Review of Published Meta-Analyses

Systematic Review with Evidence Tables

Description of the Methods Used to Analyze the Evidence

Data Extraction

The clinical and demographic characteristics and data on outcomes under investigation were extracted from primary reports. All data were independently extracted by two panellists and discrepancies were resolved by discussion.

Assessment of the Risk of Study Bias

Based on the description of methodology all included studies were evaluated for random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias that might have been detected during the review process.

Data Synthesis and Analysis

The Panel performed a meta-analysis to estimate the difference between the group with cholinesterase inhibitor (ChEI) and memantine treatment and the group with ChEI monotherapy. The data of each clinical domain (activities of daily living [ADL], behaviour, cognitive functioning, global clinical impression [GCI]), as well as serious adverse events, were pooled separately. In order to be able to pool data from different rating scales within a domain, the standardized mean difference (SMD) was chosen as the effect size. The risk difference was calculated for serious adverse events. A random effects meta-analysis with an inverse-variance weighting approach was conducted using the RevMan 5.2 software and yielded a combined SMD/risk difference with a 95% confidence interval (CI) and several measures of heterogeneity (e.g., $I^2$ index). A Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile was created using the GRADEpro software for each clinical domain and serious adverse events.

GRADE Evidence Profile

Figure 6 in the original guideline document provides the GRADE evidence profile. Based on the study design and the results of the meta-analysis this evidence profile classifies the quality of evidence in one of four levels ranging from very low to high for the overall underlying literature for each important outcome.

Methods Used to Formulate the Recommendations

Expert Consensus (Delphi)

Description of Methods Used to Formulate the Recommendations

Methods

Guideline development followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group in line with the 2012 recommendations for preparation of neurological management guidelines by the European Federation of Neurological Societies (EFNS) scientific task forces (see the "Availability of Companion Documents" field). The GRADE approach is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between advantages and disadvantages, and finally judgement about the strength of recommendations.

The Clinical Question

As in any well-conducted research study, the GRADE guideline development addresses well-designed clinical questions. Each clinical question contains the four components known by the acronym "PICO": patients; intervention; comparison; and the outcome(s) of interest, both beneficial and harmful. The PICO question was whether a combination of cholinesterase inhibitors (ChEI) plus memantine rather than ChEI alone should be used in patients with moderate to severe Alzheimer's disease (AD) in general and specifically to improve (i) global clinical impression (GCI), (ii) cognitive functioning, (iii) behaviour and (iv) activities of daily living (ADL). In line with the GRADE recommendations, when several outcomes are possible for each clinical question the GRADE approach asks panellists to make explicit judgements about the importance of each outcome for making a recommendation. Each panellist was asked to make an explicit judgement in writing using a nine-point scale with scores in the range 7-9 identifying outcomes of critical importance for decision making. Ratings between 4 and 6 characterized important but not critical outcomes and those in the range between 1 and 3 were outcomes of limited importance. The rating of the importance of the different outcomes took place prior to systematic statistical outcome evaluation. Overall, all outcomes were considered to be of critical importance with the mean of the ratings being 7.9 for ADL, 7.6 for behaviour, 7.3 for cognitive functioning, 6.3 for GCI. The importance of serious adverse events was also rated and obtained a mean score of 6.5.

Determination of the Direction and Strength of Recommendation and Consensus Finding

Determination of direction and strengths of recommendations was based on the balance between desirable and undesirable effects of combined ChEI and memantine treatment versus ChEI treatment alone, the quality of evidence, values and preferences and costs. For details refer to the EFNS guidance for preparation of neurological management guidelines. Direction was a recommendation "for" or "against" combined ChEI and memantine treatment, and the strength of recommendation had only two levels: "strong" or "weak". Recommendations were given for each outcome. Consensus was reached by use of the Delphi method during which panellists answered a questionnaire, working independently without meeting in person. After each round, a panellist served as a facilitator and provided an anonymous summary of the panellists' opinions from the previous
round, and participants were encouraged to revise their earlier answers in light of the replies from other members of the group.

**Direction and Strength of Recommendation**

Agreement of panellists was reached after the second round of the consensus finding procedure. All panellists agreed already in the first round that, compared to ChEI monotherapy, the desirable effects of combined ChEI and memantine treatment outweigh undesirable effects in patients with moderate to severe AD. With one exception there existed also agreement in the first round that the general recommendation in favour of combination therapy is weak. All panellists gave a weak recommendation for ADL, a strong recommendation for behaviour with two exceptions and a weak recommendation for cognition and GCI with three exceptions. In the second round all panellists agreed on recommendations in favour of combined ChEI plus memantine treatments as summarized in Table 2 in the original guideline document.

**Rating Scheme for the Strength of the Recommendations**

Guideline development followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group. Direction was a recommendation "for" or "against" combined cholinesterase inhibitor (ChEI) and memantine treatment, and the strength of recommendation had only two levels: "strong" or "weak."

**Cost Analysis**

It is well established that behavioural symptoms in patients with Alzheimer’s disease (AD) are associated with higher care costs than in AD patients with no or little behavioural change. A 1-point increase on the neuropsychiatric inventory (NPI), which is a tool to assess dementia-related behavioural symptoms with a maximum score of 144, increases the annual care costs by US $247–409. Therefore the approximately 3 point difference on NPI between cholinesterase inhibitors (ChEI) monotherapy and combination therapy translates into substantial cost savings.

**Method of Guideline Validation**

**Description of Method of Guideline Validation**

All authors reviewed the manuscript prior to submission. The guidelines were validated according to the European Federation of Neurological Societies (EFNS) criteria (see the "Availability of Companion Documents" field).

**Recommendations**

**Major Recommendations**

The Panel suggests that the use of a combination of cholinesterase inhibitor (ChEI) plus memantine rather than ChEI alone may provide useful benefits in patients with moderate to severe Alzheimer’s disease (AD). Despite statistically significant differences, the observed treatment effects remain modest in terms of clinical management of individual patients. The strength of the evidence for use of the combination for moderate to severe AD varied between the four domains. It was strong for patients with behavioural symptoms. The overall strength of recommendation was weak.

**Clinical Algorithm(s)**

None provided

**Evidence Supporting the Recommendations**

**Type of Evidence Supporting the Recommendations**

The recommendation is based on a systematic review and meta-analysis of randomized controlled trials based on a literature search in ALOIS, the register of the Cochrane Dementia and Cognitive Improvement Group.

**Benefits/Harms of Implementing the Guideline Recommendations**

**Potential Benefits**

The meta-analysis suggests a small but significant benefit of combined cholinesterase inhibitor (ChEI) plus memantine treatment over ChEI treatment alone on behaviour, cognitive functions and global clinical impression (GCI), with no evidence for major differences in the rate of serious adverse events with combination as opposed to monotherapy.

**Potential Harms**

See Table 1 in the original guideline document for baseline characteristics and frequency of serious adverse events of included studies.

**Qualifying Statements**

**Qualifying Statements**

Guideline development was based on the opinion of 17 researchers from 12 countries in the setting of the European Federation of Neurological Societies (EFNS)/European Neurological Society (ENS) dementia panel, and it is thus likely that the opinions expressed represent a European view.

**Implementation of the Guideline**

**Description of Implementation Strategy**

An implementation strategy was not provided.

**Implementation Tools**

Staff Training/Competency Material

For information about availability, see the Availability of Companion Documents and Patient Resources fields below.

**Institute of Medicine (IOM) National Healthcare Quality Report Categories**

**IOM Care Need**

Getting Better
Living with Illness
Identifying Information and Availability

Bibliographic Source(s)

Adaptation
Not applicable: The guideline was not adapted from another source.

Date Released
2015 Jun

Guideline Developer(s)
European Academy of Neurology - Medical Specialty Society

Source(s) of Funding
There was no funding.

Guideline Committee
European Federation of Neurological Societies (EFNS)/European Neurological Society (ENS) Dementia Panel

Composition of Group That Authored the Guideline
Panel Members: R. Schmidt, Department of Neurology, Medical University of Graz, Graz, Austria; E. Hofer, Department of Neurology, Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria; F. H. Bouwman, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands; K. Buerger, Institute for Stroke and Dementia Research (ISD), Klinikum der Universität München, Campus Großhadern, Munich, Germany; C. Cordonnier, Department of Neurology, Univ Lille Nord de France, UDSL, CHU Lille, Lille, France; T. Fladby, Department of Neurology, Akerhus University Hospital, Ahus, Norway; D. Galimberti, Neurology Unit, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ospedale Maggiore Policlinico, Fondazione Ca Granda, Milan, Italy; J. Georges, Alzheimer Europe, Luxembourg City, Luxembourg; M. T. Heneka, Clinic and Polyclinic for Neurology, Clinical Neuroscience Unit, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany; J. Hort, Second Faculty of Medicine, Department of Neurology, Charles University in Prague and Motol University Hospital, Prague 5, International Clinical Research Centre, St Anne’s University Hospital, Brno, Czech Republic; J. Laczo, Second Faculty of Medicine, Department of Neurology, Charles University in Prague and Motol University Hospital, Prague 5, International Clinical Research Centre, St Anne’s University Hospital, Brno, Czech Republic; J. L. Molinuevo, Alzheimer’s Disease and other Cognitive Disorders Unit, Department of Neurology, Hospital Clinic, IDIBAPS, Barcelona, Spain; J. T. O’Brien, Department of Psychiatry, University of Cambridge, Level E4 Cambridge Biomedical Campus, Cambridge, UK; D. Religa, Karolinska Institutet Alzheimer Disease Research Centre, Karolinska University Hospital, Stockholm, Sweden, Mosaakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland; P. Scheltens, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands; J. M. Schott, Dementia Research Centre, Institute of Neurology, UCL Queen Square, London, UK; S. Sorbi, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy

Financial Disclosures/Conflicts of Interest
Reinhold Schmidt received honoraria for consultancy from Pfizer and Axon Neuroscience. Edith Hofer reported no potential conflict of interest. Femke H Bouwman received grant money from General Electrics. Katharina Bürger received payments for lectures from Merz Pharmaceuticals and reimbursements for participation in observational studies from Merz Pharmaceuticals and Eli Lilly and for participation in clinical trials from Genentech and Servier. Charlotte Cordonnier was board member for Bayer. Tormod Fladby reported no potential conflict of interest and Daniela Galimberti reported also no potential conflict of interest. Jean Georges served as board member for GSK, provided consultancy services from Pfizer and received honoraria for lectures from Lundbeck. Michael Heneka reported reimbursement for advisory board meeting attendance from Novartis and payment for lectures from Nutricia. Jakub Hort was reimbursed for board memberships from Elian, Sotio, Alzheon, Axon Neurosciences and Merck and for consultancy for Pfizer, Lundbeck, Elian, Axon Neurosciences, Novartis, Alzheon, Merck and Sotio; he received payments for lectures from Novartis, Lundbeck, Zentiva and Eltela and holds stocks from Alzheon, Polymphinia. Jan Laczo holds stocks from Polymphinia TS Ltd. Jose Luis Molinuevo received payments for board membership by Lundbeck, MSD, BMS, GE, Novartis, Immunogenetics, and for lectures from Lundbeck, Piramal, GE, Eli Lilly, Novartis and Pfizer. John O’Brien received honoraria for consultancy from GE, TauRx and Cyboxx; he received research grants from NIHR and Avid and payments for lectures from GE and Eli Lilly. Dorota Religa reported no potential conflict of interest. Philip Scheltens received grants from GE Healthcare and Merck, honoraria for consultancy from Sanofi, TauRx, Janssen, Nutricia and Takeda, and payment for development of educational presentations from GE and for travel from Roche. Jonathan Schott received grant funding from Alzheimer’s Research UK, the UK Alzheimer’s Society, Medical Research Council, Engineering and Physical Sciences Research Council and Eli Lilly. He also received reimbursement for consultancy for Eli Lilly, payments for lectures for the BMJ group and royalties for Henry Stewart Talks. Sandro Sorbi reported no conflict of interest.

Guideline Status
This is the current release of the guideline.
This guideline meets NGC’s (2013) revised inclusion criteria.

Guideline Availability
Available to subscribers on the European Journal of Neurology Web site.

Availability of Companion Documents
The following are available:
- Continuing Medical Education questions are available to registered users from the European Academy of Neurology Web site.

Patient Resources
None available

NGC Status
This NGC summary was completed by ECRI Institute on January 6, 2016. The information was verified by the guideline developer on January 19, 2016.